NCT07678580 Tislelizumab Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07678580—Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07678580 is a hot trial to watch

Locally Advanced Esophageal Squamous Cell Carcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07678580 is notable because it evaluates Tislelizumab in a Phase 2 design while The primary outcome measure is the rate of pathological complete response (pCR) after completion of neoadjuvant treatment. Pathological complete response is defined as the absence of residual invasive cancer cells in the primary esophageal tumor bed and all sampled regional lymph nodes, confirmed by postoperative pathological examination by a qualified pathologist. serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment. Planned enrollment of 50 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: The primary outcome measure is the rate of pathological complete response (pCR) after completion of neoadjuvant treatment. Pathological complete response is defined as the absence of residual invasive cancer cells in the primary esophageal tumor bed and all sampled regional lymph nodes, confirmed by postoperative pathological examination by a qualified pathologist. (Within 1 week after surgical resection.)
• Secondary: Major pathological response is defined as the residual tumor burden being ≤10% of the primary tumor bed. This outcome measures the proportion of participants who achieve major pathological response after receiving the study intervention, reflecting the effectiveness of the treatment regimen in reducing tumor burden. (Within 1 week after surgical resection)
• Secondary: R0 resection rate refers to the proportion of participants who achieve complete surgical resection with negative surgical margins (no residual tumor tissue at the resection edges), which is an important indicator of surgical efficacy and long-term prognosis. (At the time of surgical resection)
• Secondary: To evaluate the incidence, type and severity of treatment-related adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 in all enrolled participants. (From start of neoadjuvant treatment through 30 days after last study treatment)
• Secondary: The proportion of participants achieving complete response (CR) or partial response (PR) evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to surgical resection)

Benchmark readouts in the surrounding field

• A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas (Phase 2): pCR = 0 Participants
• Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002) (Phase 2): PFS(1-year): HR = 0.54(95.0% CI, 0.32 - 0.94); PFS(1-year): HR = 0.54(95.0% CI, 0.32 - 0.94)
• Immunotherapy-based total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cancer: Interim results of a randomized phase 2 study. (Phase 2): pCR = 76.2 % ; pCR = 63.2 %

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Tislelizumab (Approved; PD-1); Albumin-Bound Paclitaxel (Approved; Tubulin); Carboplatin (Approved; DNA)

Company & Deal Intelligence context: Tangdu Hospital — China

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

NCT07678580 is a focused lens on Locally Advanced Esophageal Squamous Cell Carcinoma development. Its value will be determined by whether Tislelizumab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.